Dendreon

...decision on the biotech's Provenge prostate cancer drug by May 1, 2010. The Seattle biotech (NASDAQ: DNDN) said the FDA provided written acknowledgment of Dendreon's application for Provenge. When it's approved, "Provenge would...

In this article: FDA, DNDN, Seattle, Cancer, Nasdaq, Los Angeles, Atlanta, and New Jersey

Seattle-based Dendreon (NASDAQ: DNDN), the developer of what it hopes will be the first FDA-approved treatment to actively stimulate the immune system against cancer, said today the U.S. regulatory agency has received its amended application...

In this article: FDA, Cancer, Seattle, WordPress, Twitter, and Nasdaq

...at $356 million. The companies aren't saying how much of that is going to the Verathon shareholders. -Seattle-based Dendreon (NASDAQ: DNDN), the king of the moment in Seattle biotech, issued a pretty vanilla quarterly report with the...

In this article: Seattle, Cancer, Bothell, Roper Industries, Nasdaq, Rheumatoid arthritis, Institute for Systems Biology, and University of Washington

...Reuters First Call expected a loss of 21 cents per share and revenues of $580,000. In the latest quarter, the Seattle biotech (NASDAQ: DNDN) reported a one-time $19.4 million charge related to revaluation of warrants. Company officials...

In this article: Revenue, U.S. Food and Drug Administration, Cancer, DNDN, Nasdaq, and Seattle

...of fighting tumors, by stimulating the immune system to fight cancer cells like a virus, Seattle-based Dendreon (NASDAQ: DNDN) showed it could extend lives of terminal prostate cancer patients by a median of four months time with minimal side...

In this article: Cancer, Testosterone, Apple Tree Partners, Seattle, and Tokai Pharmaceuticals

...its first drug, sipuleucel-T, (Provenge) in the U.S. This filing came a bit earlier than Dendreon had forecasted, but it's also a lot later than the company originally hoped when it first asked the FDA for approval, which you can read...

In this article: Seattle, FDA, Institute for Systems Biology, University of Washington, Bothell, WA, Cancer, and Huntington's disease

by: VFC's Stock House November 03, 2009 | about: DNDN Shares of Dendreon (DNDN) traded as much as five percent higher on Monday morning after the company announced that it has re-submitted its application for the regulatory approval of...

In this article: FDA and Cancer

...at 9:43 AM | Page modified November 2, 2009 at 4:50 PM Dendreon completes FDA submission for cancer drug Dendreon said Monday that it completed its Food and Drug Administration application for the potential cancer drug Provenge. The drug...

In this article: Cancer, Food and Drug Administration, and Propecia

...to treat men with prostate cancer. The FDA submission was a bit earlier than expected. The company (NASDAQ: DNDN) earlier this fall said it expected to submit the drug by the middle of November. "With the BLA (Biologics License Application)...

In this article: FDA, DNDN, Cancer, Seattle, Nasdaq, Los Angeles, and Atlanta

...application came in a few days or even a few weeks ahead of schedule. Investors have been antsy for months about Dendreon (NASDAQ: DNDN) turning in its amended application to start marketing sipuleucel-T (Provenge) as the first treatment...

In this article: FDA, Cancer, Docetaxel, Seattle, Twitter, Nasdaq, and Sanofi-Aventis